Tivic Health Systems, Inc.
NCM: TIVCLive Quote
About Tivic Health Systems, Inc.
Healthcare
Medical Devices
Tivic Health Systems, Inc. operates as a late-stage immunotherapeutics company. Its lead drug candidate is Entolimod, a TLR5 agonist that is in late-stage development to treat acute radiation syndrome. The company's pipeline also comprises Entolimod to treat Neutropenia and lymphocyte exhaustion; and Entolasta, an immunologically optimized variant of Entolimod for chronic applications. In addition, it offers CDMO services. The company was incorporated in 2016 and is based in San Antonio, Texas.
📊 Fundamental Analysis
Tivic Health Systems, Inc. demonstrates a profit margin of 0.0%, which is below the sector average, suggesting competitive pressure.
Return on Equity (ROE) is -82.7%, which indicates that capital utilization is currently under pressure.
At a current price of $0.93, TIVC currently trades near the bottom of its 52-week range (2%), indicating potential value or weakness (Range: $0.72 - $13.23).
🏥 Financial Health
🔴
Profit Margin
Weak
✅
Debt/Equity
Excellent
🔴
Return on Equity
Weak
🔴
Beta (Risk)
High Volatility
Key Financials
Market Cap
$3.04M
Trailing P/E
--
Forward P/E
-0.04
Beta (5Y)
1.84
52W High
$13.23
52W Low
$0.72
Avg Volume
215K
Day High
Day Low
📡 Subscribe to ZcoreAI updates
Join the list to get access to:
- Z-Score signals at market open
- New app features and updates
- Exclusive promo for ZcoreAI App